Ovarian Cancer Prevention
Ovarian Cancer Prevention
Ovarian cancer is the cancer where the honest statement is hardest: for women at average risk there is no screening test, and the disease is usually found late. Prevention therefore runs through genetics, surgery and ovulation biology — all of them real, none of them a general-population screening programme.
First: an honest risk picture
Prevention in ovarian cancer starts with knowing which risk tier you are in, because the tiers carry different actions. Average risk — no relevant family history — means symptom awareness and nothing else: no CA-125 screening, no annual ultrasound, both of which fail as screening tools. Family pattern — the configurations described on the causes page — means a genetics referral. Known carrier — a BRCA or other repair-gene variant — means a surveillance and surgery conversation with a genetics service.
What distinguishes this cancer from almost any other common one is how much of the prevention work is done by the family tree rather than by the individual: the hereditary fraction is large, and identifying it changes the options for relatives who have not yet been affected. A woman's first act of prevention, if there is a family pattern, is to have it assessed rather than watched.
Genetic testing: who and when
Testing is earned by the family configuration: ovarian cancer in a close relative at any age; breast cancer under roughly 45; male breast cancer; multiple breast/ovarian cancers on one side; Ashkenazi ancestry with either. For a woman diagnosed with epithelial ovarian cancer herself, testing is offered regardless of family history, on blood (germline) and tumour (BRCA, HRD) — because the result drives maintenance treatment as well as the family conversation.
The sequencing is worth knowing: the affected relative is tested first; a found variant makes each relative's test a simple yes-or-no; no variant found in the affected relative means the family is tested differently or reassured. Genetic counselling frames all of it — what a result does and does not mean, and what each outcome obliges or permits.
Risk-reducing surgery
The strongest available intervention is risk-reducing salpingo-oophorectomy — removal of ovaries and fallopian tubes, performed after childbearing is complete, timed by gene and family history (typically in the forties for BRCA2 and earlier for BRCA1, individualised with the genetics team). It reduces ovarian cancer risk dramatically and, performed at the recommended ages, contributes to reduced mortality in carriers.
Two facts make it workable. The fallopian tube discovery — most high-grade serous cancers begin there — is why removing tubes alone (opportunistic salpingectomy) at any other pelvic surgery already lowers risk without ending hormones. And the surgery's costs — immediate menopause for premenopausal women — are managed deliberately, with hormone therapy discussed case by case and bone and heart health planned for. It is a decision made with a genetics service, not against one.
Ovulation-aware choices
The ovulation–risk link gives average-risk women something real to work with. Oral contraceptives reduce ovarian cancer risk, the effect strengthening with years of use and persisting for decades — a genuine secondary benefit for any woman choosing contraception. Pregnancy and breastfeeding lower risk by suppressing ovulation, relevant as context rather than as prescription. Opportunistic salpingectomy — removing the tubes during a hysterectomy or tubal procedure done for other reasons — is now offered widely as a zero-extra-incision risk reduction.
None of these is a screening strategy, and none replaces the two things that matter most: knowing the family history, and taking the persistent-symptom cluster seriously when it appears. They tilt a lifetime risk; they do not set it to zero.
What prevention cannot do
The honest boundaries, stated plainly:
- There is no screening test for average-risk women. CA-125 and ultrasound detect too few early cancers and raise too many false alarms; routine screening of average-risk women is not recommended anywhere.
- Surveillance for carriers is imperfect. Ultrasound and CA-125 in known BRCA carriers detect disease late more often than early; this is why risk-reducing surgery, not surveillance, is the primary recommendation for carriers past childbearing.
- Risk-reducing surgery changes life, not just risk. Surgical menopause has real consequences that need management; the decision is individualised, not automatic.
These limits are why the symptom cluster matters more here than in almost any other cancer: with no screening net, the persistent bloating–fullness–urgency pattern is the detection system that exists. The symptoms page sets out what earns an ultrasound.
A practical plan
For an individual woman, prevention reduces to four items with owners:
- Map the family tree — cancers, ages, sides of the family; take it to a genetics service if any pattern from the causes page appears.
- Test where the pattern warrants — and if a carrier, act on the surgery-and-surveillance conversation rather than postponing it.
- Use the ovulation levers where they fit your life — contraceptive choices, opportunistic salpingectomy at any planned pelvic surgery.
- Know the symptom cluster — and let persistence, not severity, trigger the ultrasound.
For patients of this hospital network, genetic counselling, testing and risk-reducing surgery are coordinated through the gynaecological oncology service, with reports and follow-up kept across borders.